Capstan Medical Raises $110M to Advance Robotic Heart Valve Technology for Mitral and Tricuspid Conditions

Capstan Medical's recent funding success underscores its ambitious advancements in robotic heart valve technology. The company secured $110 million in a Series C funding round, surpassing its previous $31.4 million round in August 2023, with the lead investment from Eclipse and contributions from existing investors like Intuitive Ventures, as well as a new investor, Gideon Strategic Partners[1][2]. This capital injection is crucial for progressing the company's pioneering robotic-assisted technology designed for the treatment of mitral and tricuspid valve conditions, with pivotal trials planned for 2026[1]. The funds will also facilitate team expansion and preparatory work for clinical trials, reinforcing Capstan's position at the forefront of structural heart disease innovations[2].